Abstract: A method and system for determining a hardness of a component to be tested by utilizing an ultrasonic meter. The method and system both comprise selecting a component to be tested which has a longitudinal axis; positioning a probe of the ultrasonic meter for emitting a signal from an emitter of the probe into an end surface of the component to be tested and along the longitudinal axis of the component; emitting the signal from the emitter of the probe into the first surface of the component to be tested; passing the emitted signal through the component to be tested; reflecting the emitted signal via an opposed second surface of the component to be tested back toward a detector of the probe; detecting the reflected signal via the detector of the probe; and determining a hardness of the component to be tested based upon a velocity of the emitted signal.

Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

Abstract: The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

Abstract: The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.

Abstract: A system and method for detecting wear and/or failure of a ball joint. The system having a ball housing which retains a ball head of the ball joint therein. A ball race is received within the ball housing and receives the ball head of the ball joint. An inwardly facing surface of the ball race engages the bail head such that the ball head can pivot in relation to the ball housing. A detection component is supported by the ball race and is spaced from an exterior surface of the ball head by a set distance. The detection component issues an indicator signal to alert a driver when the detection component detects at least one of a worn or a failure condition of the ball joint.

Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

Abstract: A method and system for determining a hardness of a component to be tested by utilizing an ultrasonic meter. The method and system both comprise selecting a component to be tested which has a longitudinal axis; positioning a probe of the ultrasonic meter for emitting a signal from an emitter of the probe into an end surface of the component to be tested and along the longitudinal axis of the component; emitting the signal from the emitter of the probe into the first surface of the component to be tested; passing the emitted signal through the component to be tested; reflecting the emitted signal via an opposed second surface of the component to be tested back toward a detector of the probe; detecting the reflected signal via the detector of the probe; and determining a hardness of the component to be tested based upon a velocity of the emitted signal.

Abstract: A method for forming a control arm is provided. The method includes providing an insert and a mold and also includes overcasting the insert within a metal in the mold. The insert defines a recess that is shaped for receiving a mating component. After the insert is overcast within the metal, the mating component may be positioned or mounted within the recess of the insert. A related control arm is also provided.

Abstract: A method for forming a control arm is provided. The method includes providing an insert and a mold and also includes overcasting the insert within a metal in the mold. The insert defines a recess that is shaped for receiving a mating component. After the insert is overcast within the metal, the mating component may be positioned or mounted within the recess of the insert. A related control arm is also provided.

Abstract: In accordance with the present invention, there are provided compositions comprising zanamivir and at least one permeability enhancer. The compositions can increase the amount of zanamivir capable of being transported across a cell membrane (such as a Caco-2 cell membrane), and can increase this amount by at least 150% relative to the amount capable of being transported across the cell membrane in the absence of the permeability enhancer. Also provided are oral dosage forms of the compositions, which comprise a therapeutically effective amount of zanamivir and a permeability-enhancing amount of a permeability enhancer. The oral dosage forms can further comprise an enteric- or pH-sensitive coating or layer surrounding the composition. Also provided in accordance with the present invention are methods for treating or preventing influenza infection.

Abstract: A restricted ball joint may include a passage that has a sidewall, which restricts the oscillation of the ball joint by restricting the range of motion of a shaft or stud that extends at least partially into the passage and makes contact with the sidewall when the ball joint is at a point of maximum oscillation. The ball joint may be restricted in one, two, or three axes. Restricting the ball joint in one or more axes may reduce stress on the ball joint due to flop because the loading of a vehicle tie rod may be carried by the neck of the shaft or by a stud extending from the ball shaft away from the stud when the passage is located opposite the shaft.

Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

Abstract: Disclosed is a method for manufacturing a multilayered duplex material article. The method comprises providing a first layer from a non-cast material and a second layer from a cast material wherein the second layer is made from a material with a lower melting point than the first layer. In one embodiment the first layer is a wrought alloy and the second layer is cast onto the first layer.

Abstract: A method and system for providing recommendations or targeted content to a user of a user apparatus comprising: presenting a user preference survey 130 with one or more options for election on the user apparatus 11a-11c, for each survey, receiving and storing the result of the survey to create or update a user profile 130, identifying other users 150 that match the user based on respective user profiles 130, and providing targeted content and/or recommendations of targeted content to the user apparatus 11a-11c, being content preferred by one or more of the matching users 150.

Abstract: A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.